Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E10A in Recurrent/Unresectable Head and Neck Squamous Cell Carcinoma
NCT02630264Phase 3Unknown
- Sponsor
- Guangzhou Doublle Bioproduct Co., Ltd.
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 3 trial of Recombinant human endostatin adenovirus in head and neck squamous cell carcinoma (HNSCC), sponsored by Guangzhou Doublle Bioproduct Co., Ltd.. Status: unknown.
02
Drugs
Recombinant human endostatin adenovirus
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02630264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630264.